Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Eyenovia, Inc.

Eyenovia is a public eye care company that provides topical ophthalmic therapies, including the Optejet®, an FDA-approved ophthalmic spray alternative to eye drops.

Eyenovia

Eyenovia, Inc. | 7,268 followers on LinkedIn. FDA Approved Drug-Device Ophthalmic Company | Eyenovia, Inc. (NASDAQ: EYEN), is an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications.

Sean Ianchulev MD MPH

Partner, Reillen Group, LLC

Ellen Strahlman

Julie Whitcomb, PhD

John Gandolfo

Indianapolis is now best known for the INDY500 and Eyenovia's 2024 AAOpt Ad Board! Eyenovia had the privilege of engaging with a distinguished group of optometric leaders at our American Academy Of Optometry advisory board meeting. Together, we explored the transformative potential of Clobetasol to revolutionize eye care, along with the exciting future of MydCombi. The insightful discussions provided valuable perspectives that will help us accelerate launch developments for the next-generation ophthalmic steroid and more innovative solutions. We are deeply grateful for the time, expertise, and passion our advisors share. Your guidance is vital as we continue to push boundaries and advance the future of eye care. Thank you for joining us on this journey! Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com Interested in more information and how to get MydCombi? mydcombi.com Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #eyecare #AAOPT #AAOPT2024

Discover the future of pupil dilation at AAOpt 2024 with a Phase 4 study on MydCombi! Led by Josianne Manasse, OD and Denise Pensyl, OD from SUNY College of Optometry. When: Friday, November 8, 2024 Where: AAOpt - Indianapolis Location: Exhibit Hall H, Poster Board #109 Time: 1:00-3:00 PM Learn more about MydCombi: https://bit.ly/mydcombi Contraindications: Known hypersensitivity to any component of the formulation. See Full Prescribing Information Here: https://bit.ly/4btbPHk” Learn how Eyenovia is making it possible by visiting https://bit.ly/3Dik87F #AAOpt2024 #ophthalmology #optometry #eyenovia #optejet #drugdevice #technology #tech #investing #innovation #startups #mydcombi

Shelley Malkemus , a legend in ophthalmology, is happily heading to retirement! After years of dedication, attention to detail, and countless moments of support for the Eyenovia team and the industry, Shelley is officially closing this chapter of her remarkable career. But don't think she's slowing down! Shelley is taking on a brand-new role as a full-time Grammy, stepping into her next adventure with open arms as her family grows and welcomes another precious grandchild. Thank you, Shelley, for everything you’ve done to keep us on track and inspired. We wish you all the best in this exciting new phase—one that comes with more hugs, playdates, and plenty of love. 💙 Happy Retirement, Shelley!

Blink, and it’s gone! It’s been just over a week since the American Academy of Ophthalmology , and Eyenovia extends its sincere thanks to the ophthalmic leaders who attended our AAO 2024 Advisory Board in Chicago. The thoughtful and engaging discussions surrounding our products were invaluable, providing key insights that will help propel the momentum behind our commercial launches of Clobetasol and MydCombi even further. We are excited to incorporate these perspectives as we continue to advance our portfolio. Thank you once again to our esteemed advisors for an evening of productive discussion and shared learning! Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com Interested in more information and how to get MydCombi? mydcombi.com Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare #AAO2024

The latest addition to the Socialite Vision family Eyenovia, Inc. thanks Paul S. Mike Ruiz

Dr. Adam Ramsey

Thank you, Francis Mah, MD, for being among the early adopters of Clobetasol, the next-generation ophthalmic steroid! We are pleased to see that you are actively prescribing Clobetasol for your patients. Renowned for his contributions as an ophthalmologist and respected researcher, speaker, and thought leader, Dr. Mah is dedicated to enhancing patient outcomes through innovative treatment approaches. Clobetasol empowers him to deliver powerful, swift relief from post-surgical pain and inflammation. With twice-a-day dosing, this state-of-the-art treatment has the potential to deliver quicker recovery times and improved overall patient experience. Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/ Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare INDICATIONS AND USAGE: Clobetasol Propionate Ophthalmic Suspension 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Full Prescribing Information: https://lnkd.in/gWYjgSiN

Dagny Zhu, M.D. , the Medical Director and Partner of NVISION Eye Centers Rowland Heights, was one of the first in the US to implement Clobetasol into her practice and post-operative patient care. She stated, "I’m excited for the ease of twice-a-day dosing for our patients. I also look forward to using Clobetasol to treat postop inflammation in our surgical patients with greater peace of mind as the data suggests a low risk of IOP spikes." As a key opinion leader in advanced cataract surgery and LASIK surgery, Dr. Zhu has been featured in over 200 lectures, presentations, publications, and press features. We are thrilled to have an expert like herself using Clobetasol! Learn more about NVISION and Dr. Zhu: https://lnkd.in/gJ5rfZbQ Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/ Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare INDICATIONS AND USAGE: Clobetasol Propionate Ophthalmic Suspension 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Full Prescribing Information: https://lnkd.in/gWYjgSiN

I’m proud to be the first in Florida to partner with Eyenovia to offer the next generation in ophthalmic steroid drops. This has the potential to revolutionize post operative inflammation and optimize healing for our patients. Check out the science behind Clobetasol Propionate for you eye nerds 🤓Congrats Eyenovia! 👏 Photo used with my wonderful patient’s permission. Here’s to innovation in surgical postoperative management! Its twice-a-day indication is great 🙌 Paul S. Mike Ruiz #surgery #ophthalmology Eyenovia, Inc. #eyehealth #glaucoma #cataract #gaass #SLT Ehsan Sadri MD FACS

Matthew Brink

Thank you to Eyewire+ News for highlighting the US launch of Clobetasol! We are thrilled to see the positive reception of this innovative treatment, and we appreciate the support from Eyewire in sharing this milestone. We envision Clobetasol as a game-changer for post-operative outcomes and are proud to introduce this next-generation steroid to the eye care market. Check out the full video here: https://lnkd.in/gdMHmsbP Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/ Learn how Eyenovia is making it possible by visiting: https://bit.ly/3Dik87F #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare Contraindications: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. See Full Prescribing Information Here: https://lnkd.in/gWYjgSiN

AND WE'RE OFF! Clobetasol is now available to eye care physicians across the US. We are excited to offer the next generation ophthalmic steroid which is designed to be easy for prescribers and their patients. Go to ClobetasolBID.com to learn more about the product and for ordering information. To read our latest press release: https://lnkd.in/gZFNKqry #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare Contraindications: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. See Full Prescribing Information Here: https://lnkd.in/gWYjgSiN

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue						2M -	14M 600%		3.79K -
cost of revenue						800K -	1.60M 100%		787.00K -
gross profit						1.20M -	12.40M 933.33%		-783.21K -
selling and marketing expenses								1.20M -	1.10M 8.84%
general and administrative expenses	1.49M -	568.77K 61.73%	1.32M 131.31%	6.14M 366.49%	7.21M 17.41%	7.73M 7.21%	10.79M 39.72%	13.53M 25.37%	11.33M 16.25%
selling general and administrative expenses	1.49M -	568.77K 61.73%	1.32M 131.31%	6.14M 366.49%	7.21M 17.41%	7.73M 7.21%	10.79M 39.72%	13.53M 25.37%	12.42M 8.19%
research and development expenses	2.78M -	2.97M 6.57%	3.82M 28.68%	11.12M 191.33%	14.10M 26.83%	13.26M 5.95%	14.51M 9.39%	13.38M 7.79%	12.20M 8.81%
other expenses						-10K -	47.18K 571.83%	197.09K 317.71%	-176.41K 189.51%
cost and expenses	4.27M -	3.53M 17.21%	5.13M 45.19%	17.26M 236.23%	21.31M 23.48%	21.78M 2.21%	26.90M 23.53%	26.91M 0.03%	25.41M 5.58%
operating expenses	4.27M -	3.53M 17.21%	5.13M 45.19%	17.26M 236.23%	21.31M 23.48%	20.98M 1.55%	25.30M 20.61%	26.91M 6.35%	24.62M 8.50%
interest expense						17.04K -	387.76K 2,175.30%	1.38M 255.91%	2.37M 71.87%
ebitda	-4.26M -	-3.52M 17.32%	-5.13M 45.72%	-17.26M 236.23%	-21.31M 23.48%	-19.75M 7.30%	-12.85M 34.93%	-26.63M 107.18%	-24.62M 7.54%
operating income	-4.27M -	-3.53M 17.21%	-5.13M 45.19%	-17.26M 236.23%	-21.31M 23.48%	-19.78M 7.18%	-12.90M 34.76%	-26.91M 108.56%	-25.41M 5.59%
depreciation and amortization	9.70K -	12.80K 32.01%	25.47K 98.92%	19.13K 24.88%	15.34K 19.79%	26.40K 72.07%	49.70K 88.25%	280.42K 464.23%	783.21K 179.30%
total other income expenses net	2.41K -	1.50K 37.94%	2.38K 58.98%	3.33K 40.13%	151.79K 4,451.30%	9.36K 93.83%	125.30K 1,238.92%	-1.10M 977.64%	-1.85M 68.66%
income before tax	-4.27M -	-3.53M 17.20%	-5.13M 45.18%	-17.25M 236.32%	-21.16M 22.63%	-19.77M 6.56%	-12.78M 35.36%	-28.01M 119.21%	-27.26M 2.68%
income tax expense			-25.47K -	3.33K 113.10%	-167.13K 5,111.36%	-78.37K 53.11%	213.38K 372.26%		2 -
net income	-4.27M -	-3.53M 17.20%	-5.13M 45.18%	-17.25M 236.32%	-20.99M 21.66%	-19.69M 6.18%	-12.99M 34.02%	-27.73M 113.45%	-27.26M 1.69%
weighted average shs out	9.94M -	9.94M 0%	9.94M 0.00%	9.48M 4.63%	14.35M 51.42%	21.05M 46.73%	26.32M 25.03%	33.65M 27.83%	41.03M 21.94%
weighted average shs out dil	9.94M -	9.94M 0%	9.94M 0.00%	9.48M 4.63%	14.35M 51.42%	21.05M 46.73%	26.32M 25.03%	33.65M 27.83%	41.03M 21.94%
eps	-0.43 -	-0.36 16.28%	-0.52 44.44%	-1.82 250%	-1.46 19.78%	-0.94 35.62%	-0.49 47.87%	-0.82 67.35%	-0.66 19.51%
epsdiluted	-0.43 -	-0.36 16.28%	-0.52 44.44%	-1.82 250%	-1.46 19.78%	-0.94 35.62%	-0.49 47.87%	-0.82 67.35%	-0.66 19.51%

COM:EYENOVIA

Eyenovia

Last Close

0.11

22/11 21:00

Market Cap

57.71M

Beta: -

Volume Today

29.55M

Avg: -

Preview